Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases

Cancer Immunology, Immunotherapy

Volumn 64, Issue 3, 2015, Pages 381-388

  Wilgenhof, Sofie ^a,b   Corthals, Jurgen ^b   Van Nuffel, An M T ^b   Benteyn, Daphné ^b   Heirman, Carlo ^b   Bonehill, Aude ^b   Thielemans, Kris ^b   Neyns, Bart ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Dendritic cell; Immunotherapy; Interferon alpha 2b; Melanoma; mRNA

Indexed keywords

ALPHA2B INTERFERON; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; HLA ANTIGEN CLASS 2; MELAN A; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; ALPHA INTERFERON; CANCER VACCINE; MELANOMA ANTIGEN; MLANA PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; DENDRITIC CELL; DEPIGMENTATION; DEPRESSION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HYPERTHYROIDISM; INJECTION SITE REACTION; INTRADERMAL DRUG ADMINISTRATION; LYMPHADENOPATHY; MALE; MELANOMA; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN TARGETING; RECURRENCE FREE SURVIVAL; SARCOIDOSIS; ADOPTIVE IMMUNOTHERAPY; CLINICAL TRIAL; ELECTROPORATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; CANCER VACCINES; DENDRITIC CELLS; ELECTROPORATION; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; MALE; MART-1 ANTIGEN; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM METASTASIS; PILOT PROJECTS; RECOMBINANT PROTEINS; RNA, MESSENGER; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84925493908     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1642-8     Document Type: Article

References (40)

1. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206
2. Eggermont AM, Suciu S, Testori A et al (2012) Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30:3810–3818
3. Sondak VK, Kudchadkar R (2012) Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role? Oncologist 17:1223–1224
4. Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493–501
5. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
6. Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365
7. Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114
8. Hodi F, O’Day S, McDermott D et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
9. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526
10. Eggermont AM, Chiarion-Sileni V, Grob JJ et al (2014) Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO Meeting Abstracts, Alexandria 32
11. Boon T, Coulie P, Van den Eynde B, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175–208
12. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135–146
13. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265–277
14. Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie P (2008) Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res 68:3931–3940
15. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der Bruggen P, Thielemans K (2004) Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 172:6649–6657
16. Michiels A, Breckpot K, Corthals J, Tuyaerts S, Bonehill A, Heirman C, Thielemans K, Aerts JL (2006) Induction of antigen-specific CD8 + cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther 13:1027–1036
17. Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, Neyns B, Thielemans K (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16:1170–1180
18. Mitchell M, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell W, Groshen S (1994) Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 12:402–411
19. Astsaturov I, Petrella T, Bagriacik E et al (2003) Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res 9:4347–4355
20. Di Pucchio T, Pilla L, Capone I et al (2006) Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 66:4943–4951
21. Mitchell M, Abrams J, Thompson J et al (2007) Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol 25:2078–2085
22. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L (2009) Immunogenicity and antitumor effects of vaccination with peptide vaccine ± granulocyte–monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 15:1443–1451
23. Schwartzentruber DJ, Lawson DH, Richards JM et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119–2127
24. Yuan J, Gnjatic S, Li H et al (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105:20410–20415
25. Ribas A, Comin-Anduix B, Chmielowski B et al (2009) Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267–6276
26. Wilgenhof S, Van Nuffel AM, Corthals J et al (2011) Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34:448–456
27. Neyns B, Corthals J, De Greve J, De Greef C, Coulie PG, Thielemans K (2006) A cohort pilot study on therapeutic vaccination of advanced melanoma patients with dendritic cells loaded with multiple peptides or electroporated with mRNA. ASCO Meeting Abstracts 24: 18011
28. Neyns B, Corthals J, Thielemans K (2007) Interferon alfa-2b treatment following therapeutic vaccination with mRNA electroporated dendritic cells results in skin depigmentation and tumor regression in patients with advanced melanoma. ASCO Meeting Abstracts 25: 8537
29. Tuyaerts S, Noppe S, Corthals J, Breckpot K, Heirman C, De Greef C, Van Riet I, Thielemans K (2002) Generation of large numbers of dendritic cells in a closed system using cell factories. J Immunol Methods 264:135–151
30. Bonehill A, Van Nuffel A, Corthals J et al (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15:3366–3375
31. Van Nuffel A, Corthals J, Neyns B, Heirman C, Thielemans K, Bonehill A (2010) Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. Methods Mol Biol 629:405–452
32. Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A (2012) Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods 377:23–36
33. Van Nuffel AM, Benteyn D, Wilgenhof S et al (2012) Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4 + and CD8 + T cells in melanoma patients. Mol Ther 20:1063–1074
34. Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A (2013) Characterization of CD8(+) T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC–MEL). Biomed Res Int 2013:976383
35. Kantoff P, Higano C, Shore N et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
36. Hasebe H, Nagayama H, Sato K, Enomoto M, Takeda Y, Takahashi TA, Hasumi K, Eriguchi M (2000) Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients. Biomed Pharmacother 54:291–298
37. Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420
38. Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A (2012) Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 61:1033–1043
39. Wilgenhof S, Van Nuffel AM, Benteyn D et al (2013) A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 24:2686–2693
40. Pectasides D, Dafni U, Bafaloukos D et al (2009) Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 27:939–944